Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female child between, and including, 5 and 10 weeks of age at the time of the first study vaccination.~* Written informed consent obtained from the parent or guardian of the subject who is of legal age~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* In South Africa, birth weight \> 2000 grams or if weight unknown, gestation period \> 36 weeks.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product~* Planned administration of a vaccine not foreseen by the study protocol within 14 days before each dose of study vaccine(s) and ending 14 days after.~* Chronic administration (defined as more than 14 days) of immunosuppressants since birth.~* History of use of experimental rotavirus vaccine.~* Previous routine vaccination except Bacille Calmette-Guérin (BCG), hepatitis B virus (HBV) and oral poliovirus (OPV) vaccination at birth~* Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract, intussusception or other medical condition determined to be serious by the investigator.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination~* History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.~* Acute disease at the time of enrolment.~* Gastroenteritis within 7 days preceding the first study vaccine administration~* Previous confirmed occurrence of rotavirus gastroenteritis (RV GE).~* A family history of congenital or hereditary immunodeficiency.~* Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.~* History of any neurologic disorders or seizures.~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.

- Gender: ALL
- Minimum Age: 5 Weeks
- Maximum Age: 10 Weeks
- Healthy Volunteers: t

Study Arms:
- Rotarix 3-Dose Group (Type: EXPERIMENTAL): Subjects received 3 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
- Rotarix 2-Dose Group (Type: EXPERIMENTAL): Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
- Placebo Group (Type: PLACEBO_COMPARATOR): Subjects received 3 doses of placebo given concomitantly with routine EPI vaccines.

Based on this trial design, predict the completion outcome and termination type (if applicable).